To assess the impact of dysfunctional peritumoral lymphatics on the TME, Kataru et al. used a mouse model of local lymphatic ablation by toxin injection (LV-/-). In control mice, melanoma and breast cancer peritumoral edema was concentrated in regions lacking lymphatic vessels and expanded over time. LV-/- mice demonstrated increased melanoma tumor growth and edema, with more inflammatory and suppressive immune cells and cytokines. LV-/- mice showed fewer CD8+ T cells and increased PD-L1 expression within tumors. Lymphatic ablation in healthy tissue led to an enhanced inflammatory profile and faster carcinogen-induced tumorigenesis.

Contributed by Alex Najibi

Proliferation of aberrant, dysfunctional lymphatic vessels around solid tumors is a common histologic finding. Studies have shown that abnormalities in lymphatic function result in accumulation of inflammatory cells with an immunosuppressive profile. We tested the hypothesis that dysfunctional lymphatic vessels surrounding solid tumor regulate changes in the tumor microenvironment and tumor-specific immune responses. Using subcutaneously implanted mouse melanoma and breast cancer tumors in a lymphatic endothelial cell-specific diphtheria toxin receptor transgenic mouse, we found that local ablation of lymphatic vessels increased peritumoral edema, as compared with controls. Comparative analysis of the peritumoral fluid demonstrated increases in the number of macrophages, CD4+ inflammatory cells, F4/80+/Gr-1+ (myeloid derived suppressor cells), CD4+/Foxp3+ (T regs) immunosuppressive cells and expression of inflammatory cytokines such as TNFalpha, IFNgamma and IL1beta following lymphatic ablation. Tumors grown in lymphatic ablated mice exhibited reduced intratumoral accumulation of cytotoxic T cells and increased tumor PD-L1 expression, causing rapid tumor growth, compared with tumors grown in nonlymphatic-ablated mice. Our study suggests that lymphatic dysfunction plays a role in regulating tumor microenvironments and may be therapeutically targeted in combination with immunotherapy to prevent tumor growth and progression.

Author Info: (1) Surgery, Memorial Sloan Kettering Cancer Center katarur@mskcc.org. (2) Surgery, Memorial Sloan Kettering Cancer Center. (3) Surgery, Memorial Sloan Kettering Cancer Center. (4)

Author Info: (1) Surgery, Memorial Sloan Kettering Cancer Center katarur@mskcc.org. (2) Surgery, Memorial Sloan Kettering Cancer Center. (3) Surgery, Memorial Sloan Kettering Cancer Center. (4) Surgery, Memorial Sloan Kettering Cancer Center. (5) Surgery, Memorial Sloan Kettering Cancer Center. (6) Surgery, Memorial Sloan Kettering Cancer Center. (7) Biotechnology Porgramme, Spanish National Cancer Research Centre. (8) Department of Pediatrics, Cornell University Weill Medical College. (9) Surgery, Memorial Sloan Kettering Cancer Center.